Induction of bone formation by activated monocytes / macrophages depends on Oncostatin M signaling

Bone resorption by osteoclasts and bone formation by osteoblasts are tightly coupled processes implicating factors in TNF, bone morphogenetic protein and Wnt families. In osteoimmunology, macrophages were described as another critical cell population regulating bone formation by osteoblasts but the coupling factors were not identified. Using a high throughput approach, we identified here Oncostatin M (OSM), a cytokine of the IL-6 family, as a major coupling factor produced by activated circulating CD14 + or bone marrow CD11b + monocytes/macrophages that induces osteoblast differentiation and matrix mineralization from human mesenchymal stem cells (MSC) while inhibiting adipogenesis. Upon toll-like receptors (TLRs) activation by lipopolysaccharide or endogenous ligands, OSM was produced in classically activated inflammatory M1 and not M2 macrophages, through a cyclooxygenase-2 and prostaglandin-E2 regulatory loop. Stimulation of osteogenesis by activated monocytes/macrophages was prevented using neutralizing antibodies or siRNA to OSM, OSM receptor subunits gp130 and OSMR or to the downstream transcription factor STAT3. The induced osteoblast differentiation program culminated with enhanced expression of C/EBPδ (CCAAT-enhancer-binding protein δ), Cbfa1 and alkaline phosphatase. Overexpression of OSM in the tibia of mice has led to new bone apposition with no sign of bone resorption. Two other cytokines had also a potent role in bone formation induced by monocytes/macrophages and TLRs activation: IL-6 and Leukemia inhibitory factor. We propose that during bone inflammation, infection or injury, the IL-6 family signaling network activated by macrophages and TLR ligands stimulates bone formation that is largely uncoupled from bone resorption and is thus an important target for anabolic bone therapies. 3 \body Bone is a dynamic mineralized tissue which is continuously resorbed by osteoclasts and rebuilt by osteoblasts. Osteoclast precursors are hematopoietic cells of the monocyte/macrophage lineage whereas osteoblast precursors are multipotent mesenchymal stem cells (MSC) that can also give rise to adipocytes and chondrocytes. Under physiological conditions, bone resorption is precisely replaced by new bone formation and therefore osteoclast and osteoblast activities are tightly coupled. Indeed, osteoblasts control osteoclast differentiation mainly through RANKL (receptor activator of nuclear factor kappa-B ligand) and inversely osteoclast control osteoblast differentiation through Wnt10b and BMP6 (bone morphogenetic protein 6) for example (1, 2). Immune cells such as T lymphocytes also control bone homeostasis or pathology in a field of research called osteoimmunology. More recently, bone resident macrophages, termed osteomacs, have been described as another critical immune cell population regulating bone formation by osteoblasts (3). However the coupling factors produced by osteomacs were …

[1]  D. Hume,et al.  Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  D. Magne,et al.  TNF-α stimulates alkaline phosphatase and mineralization through PPARγ inhibition in human osteoblasts. , 2011, Bone.

[3]  M. Feldmann,et al.  TNF-α promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells , 2011, Proceedings of the National Academy of Sciences.

[4]  S. Goodman,et al.  Modulating osteogenesis of mesenchymal stem cells by modifying growth factor availability. , 2010, Cytokine.

[5]  Hélène Rouard,et al.  Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. , 2010, Blood.

[6]  T. Martin,et al.  Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. , 2010, The Journal of clinical investigation.

[7]  P. Carmeliet,et al.  Increased skeletal VEGF enhances β‐catenin activity and results in excessively ossified bones , 2010, The EMBO journal.

[8]  N. Walsh,et al.  Bone remodeling in rheumatic disease: a question of balance , 2010, Immunological reviews.

[9]  E Choy,et al.  Interleukin-6 as a key player in systemic inflammation and joint destruction. , 2009, Autoimmunity reviews.

[10]  J. Hamilton,et al.  Proinflammatory cytokines inhibit osteogenic differentiation from stem cells: implications for bone repair during inflammation. , 2009, Osteoarthritis and cartilage.

[11]  P. Tak,et al.  The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. , 2009, Arthritis and rheumatism.

[12]  D. Magne,et al.  TNF-alpha and IL-1beta inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. , 2009, Life sciences.

[13]  M. Macoritto,et al.  Autocrine Regulation of Interferon γ in Mesenchymal Stem Cells Plays a Role in Early Osteoblastogenesis , 2009, Stem cells.

[14]  F. Blanchard,et al.  The dual role of IL-6-type cytokines on bone remodeling and bone tumors. , 2009, Cytokine & growth factor reviews.

[15]  S. Khosla,et al.  Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate , 2008, Proceedings of the National Academy of Sciences.

[16]  D. Link,et al.  Granulocyte Colony‐Stimulating Factor Induces Osteoblast Apoptosis and Inhibits Osteoblast Differentiation , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  J. Mege,et al.  Macrophage Polarization in Bacterial Infections , 2008, The Journal of Immunology.

[18]  David A. Hume,et al.  Osteal Tissue Macrophages Are Intercalated throughout Human and Mouse Bone Lining Tissues and Regulate Osteoblast Function In Vitro and In Vivo1 , 2008, The Journal of Immunology.

[19]  S. Chevalier,et al.  Chronically Inflamed Human Tissues Are Infiltrated by Highly Differentiated Th17 Lymphocytes , 2008, The Journal of Immunology.

[20]  Kunihiro Matsumoto,et al.  A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-γ transactivation , 2007, Nature Cell Biology.

[21]  Nimrod Rozen,et al.  Fracture repair: modulation of fracture-callus and mechanical properties by sequential application of IL-6 following PTH 1-34 or PTH 28-48. , 2007, Bone.

[22]  Jae Hyun Kim,et al.  Oncostatin M promotes osteogenesis and suppresses adipogenic differentiation of human adipose tissue‐derived mesenchymal stem cells , 2007, Journal of cellular biochemistry.

[23]  S. Sa,et al.  The Effects of IL-20 Subfamily Cytokines on Reconstituted Human Epidermis Suggest Potential Roles in Cutaneous Innate Defense and Pathogenic Adaptive Immunity in Psoriasis , 2007, The Journal of Immunology.

[24]  A. Miyajima,et al.  Oncostatin M Inhibits Adipogenesis through the RAS/ERK and STAT5 Signaling Pathways* , 2006, Journal of Biological Chemistry.

[25]  K. Ishihara,et al.  A critical role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation. , 2006, Bone.

[26]  C. Shin,et al.  CCAAT/enhancer-binding protein delta activates the Runx2-mediated transcription of mouse osteocalcin II promoter. , 2006, Journal of molecular endocrinology.

[27]  M. Malaise,et al.  Interleukin-6: An osteotropic factor influencing bone formation? , 2005, Bone.

[28]  A. Chott,et al.  Interaction between Synovial Inflammatory Tissue and Bone Marrow in Rheumatoid Arthritis 1 , 2005, The Journal of Immunology.

[29]  M. Neurath,et al.  Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer , 2005, Clinical reviews in allergy & immunology.

[30]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[31]  C. Colombeix,et al.  Downregulation of Osteoblast Markers and Induction of the Glial Fibrillary Acidic Protein by Oncostatin M in Osteosarcoma Cells Require PKCδ and STAT3 , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  D. Rachmilewitz,et al.  Interleukin 10-deficient mice develop osteopenia, decreased bone formation, and mechanical fragility of long bones. , 2004, Gastroenterology.

[33]  R. Moots,et al.  Secretion of oncostatin M by neutrophils in rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[34]  A. Munnich,et al.  Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome. , 2004, American journal of human genetics.

[35]  L. Joosten,et al.  Growth plate damage, a feature of juvenile idiopathic arthritis, can be induced by adenoviral gene transfer of oncostatin M: a comparative study in gene-deficient mice. , 2003, Arthritis and rheumatism.

[36]  G. Lisignoli,et al.  Human osteoblasts express functional CXC chemokine receptors 3 and 5: Activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and β‐N‐acetylhexosaminidase release , 2003, Journal of cellular physiology.

[37]  U. Lerner,et al.  IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-κB Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Mouse Calvariae1 , 2002, The Journal of Immunology.

[38]  H. Koyama,et al.  Induction of Bone-Type Alkaline Phosphatase in Human Vascular Smooth Muscle Cells: Roles of Tumor Necrosis Factor-&agr; and Oncostatin M Derived From Macrophages , 2002, Circulation research.

[39]  E. Benveniste,et al.  Prostaglandin E2 Is a Novel Inducer of Oncostatin-M Expression in Macrophages and Microglia , 2002, The Journal of Neuroscience.

[40]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[41]  E. Schwarz,et al.  Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. , 2002, The Journal of clinical investigation.

[42]  Yoshiaki Ito,et al.  Runt Domain Factor (Runx)-dependent Effects on CCAAT/ Enhancer-binding Protein δ Expression and Activity in Osteoblasts* , 2000, The Journal of Biological Chemistry.

[43]  T. van der Poll,et al.  Endotoxin down-regulates monocyte and granulocyte interleukin-6 receptors without influencing gp130 expression in humans. , 2000, The Journal of infectious diseases.

[44]  M. Goldring,et al.  The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. , 1998, Arthritis and rheumatism.

[45]  John R. Johnson,et al.  The Effect of Postoperative Nonsteroidal Anti‐inflammatory Drug Administration on Spinal Fusion , 1998, Spine.

[46]  T. Vischer,et al.  Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. , 1997, The Journal of rheumatology.

[47]  S. Chevalier,et al.  Interleukin-6 Family of Cytokines Induced Activation of Different Functional Sites Expressed by gp130 Transducing Protein* , 1996, The Journal of Biological Chemistry.

[48]  K Banovac,et al.  Effect of Nonsteroidal Antiinflammatory Drugs on Fracture Healing: A Laboratory Study in Rats , 1995, Journal of orthopaedic trauma.

[49]  C. Ware,et al.  Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. , 1995, Development.

[50]  T. Libermann,et al.  Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide , 1994, Molecular and cellular biology.

[51]  D. Heymann,et al.  Direct anti-cancer effect of oncostatin M on chondrosarcoma , 2011 .

[52]  S. Rantapää Dahlqvist,et al.  Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? , 2009, Clinical and experimental rheumatology.

[53]  S. Kwan Tat,et al.  IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004, Cytokine & growth factor reviews.

[54]  J. Dewille,et al.  Oncostatin M induces growth arrest of mammary epithelium via a CCAAT/enhancer-binding protein delta-dependent pathway. , 2002, Molecular cancer therapeutics.

[55]  P. Roberson,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Activation of the Janus Kinase/STAT (Signal Transducer and Activator of Transcription) Signal Transduction Pathway by Interleukin-6-Type Cytokines Promotes , 2022 .

[56]  E. Lubberts,et al.  Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand. , 2002, The American journal of pathology.